Compare Incyte Corporation (INCY) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Innodata Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Innodata Inc trades at $61.91 (market cap $2.10B). The key difference: Incyte Corporation is far larger — about 10.9× Innodata Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Innodata Inc for 19 Days on average.
| INCY | INOD | |
|---|---|---|
Market Cap | $22.85B | $2.10B |
Volume | 1,927,029 | 989,493 |
Sector | Health | Technology |
52-Week High | $129.93 | $121.50 |
52-Week Low | $83.80 | $34.45 |
Typical Hold Time | 33 Days | 19 Days |
Enterprise Value | $18.35B | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
INOD trades at $61.54, down 2.96% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consecutive earnings beats, with Q1 2026 EPS of $0.42 significantly exceeding the $0.13 estimate, and demonstrated robust revenue growth from $252M in 2025 to $317M projected for 2026. Analyst sentiment remains positive with a 67% buy rating, though the stock faces valuation concerns with a P/E of 47.4.
The outlook for INOD is mixed: strong AI-driven revenue growth and expanding margins support upside potential, but high valuation multiples and bearish technical signals present near-term risks. Investor focus should remain on execution of new initiatives like the motion-capture AI lab and customer diversification efforts to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
